{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01662973",
      "OrgStudyIdInfo": {
        "OrgStudyId": "Beijing302-005"
      },
      "Organization": {
        "OrgFullName": "Beijing 302 Hospital",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis",
      "OfficialTitle": "Phase 1/2 Study of UC-MSC Treatment for Evaluation the Efficacy and Safety in Patients With Primary Biliary Cirrhosis"
    },
    "StatusModule": {
      "StatusVerifiedDate": "May 2013",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "October 2011"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "October 2013",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "October 2013",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "August 5, 2012",
      "StudyFirstSubmitQCDate": "August 9, 2012",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "August 13, 2012",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "May 30, 2013",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "May 31, 2013",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Fu-Sheng Wang",
        "ResponsiblePartyInvestigatorTitle": "Director of both the Research Center for Biological Therapy and the Beijing Institute of Translational Hepatology",
        "ResponsiblePartyInvestigatorAffiliation": "Beijing 302 Hospital"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Beijing 302 Hospital",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Primary biliary cirrhosis (PBC) is a slowly progressive disease that causes substantial loss of intrahepatic bile ducts, ultimately resulting in cholestasis, advanced fibrosis, cirrhosis, liver failure and even hepatocellular carcinoma. Histologically, the disease is characterized by chronic portal inflammation with infiltration, destruction and loss of the epithelial cells in the small-sized and medium-sized bile ducts. Currently, Ursodeoxycholic acid (UDCA) in a dose of 13-15mg/kg/day is recommended as therapeutic drugs for PBC by AASLD and is approved for this indication by the U.S. Food and Drug Administration (FDA). Treatment with UDCA may delay disease progression and prolong survival free of liver transplantation. However, one out of three patients does not adequately respond to UDCA therapy and many need additional medical therapy or liver transplantation, or both. UC-MSC has been application for the treatment of several severe autoimmune diseases, such as immune thrombocytopenia, systemic lupus erythematosus, and therapy-resistant rheumatoid arthritis. In this study, the safety and efficacy of UC-MSC transplantation for PBC patients will be evaluated.",
      "DetailedDescription": "Primary biliary cirrhosis (PBC) is a slowly progressive cholestatic disease associated with the development of cirrhosis and liver failure that may justify liver transplantation. Ursodeoxycholic acid (UDCA) is currently the only drug approved specifically for the treatment of PBC. However, one out of three patients does not adequately respond to UDCA therapy and many need additional medical therapy or liver transplantation, or both.\n\nThe potential for stem cells to differentiate into biliary epithelial cells was recently confirmed. In particular, bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation has been applicated in the clinic for treat several human disease such as GVHD, cardiac injury and brain injury, and displayed good tolerance and efficiency. Recently, umbilical cord-derived MSCs (UC-MSC) has also been used to treat severe autoimmune diseases, such as therapy-resistant rheumatoid arthritis and multiple sclerosis.\n\nThe purpose of this study is to learn whether and how UC-MSC can improve the disease condition in patients with primary biliary cirrhosis. This study will also look at how well UC-MSC is tolerated and its safety in PBC patients\n\nParticipants in the study will be randomly assigned to one of two treatment arms:\n\nArm A: Participants will receive 12 weeks of UC-MSC treatment plus UDCA. Arm B: Participants will receive 12 weeks of placebo plus UDCA. UC-MSC will be prepared according to standard procedures and is collected in plastic bags containing anticoagulant. UC-MSCs are given via i.v. under sonography monitoring. After cell therapy, patients are followed up at week 4,8,12,24,36 and 48. The evaluation of some clinical parameters such as the level of serum alkaline phosphatase (ALP), alanine aminotransferase(ALT) aspartate aminotransferase (AST) and total bilirubin (TB), prothrombin time(PT), albumin(ALB), prealbumin(PA), are detected at these time points. Mayo risk score, portal hypertension, Liver histology, MELD score and clinical symptoms were also observed simultaneously."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Primary Biliary Cirrhosis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Primary Biliary Cirrhosis",
          "Mesenchymal Stem Cells",
          "Serum alkaline phosphatase",
          "Serum Bilirubin"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "100",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Conventional plus UC-MSC treatment",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.\n\nParticipants will then be followed until the week 48 study visit.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: conventional plus UC-MSC treatment"
              ]
            }
          },
          {
            "ArmGroupLabel": "Conventional plus placebo treatment",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Conventional plus placebo treatment"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Other",
            "InterventionName": "conventional plus UC-MSC treatment",
            "InterventionDescription": "Received conventional treatment and taken i.v., once per 4 week, at a dose of 1*10E6 UC-MSC/kg body weight for 12 weeks.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Conventional plus UC-MSC treatment"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Conventional plus placebo treatment",
            "InterventionDescription": "Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Conventional plus placebo treatment"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Serum alkaline phosphatase (ALP)",
            "PrimaryOutcomeTimeFrame": "0, 4, 8,12, 24, 36,48 weeks after treatment"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Histological changes in liver biopsies",
            "SecondaryOutcomeTimeFrame": "baseline and 48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Serum Bilirubin",
            "SecondaryOutcomeTimeFrame": "At base line and at week 4,8,12,24,36 and 48"
          },
          {
            "SecondaryOutcomeMeasure": "Serum AST",
            "SecondaryOutcomeTimeFrame": "At base line and at week 4,8,12,24,36 and 48"
          },
          {
            "SecondaryOutcomeMeasure": "Mayo risk score",
            "SecondaryOutcomeTimeFrame": "At base line and at week 4,8,12,24,36 and 48"
          },
          {
            "SecondaryOutcomeMeasure": "Number of patients with Portal Hypertension after 12 weeks treatment",
            "SecondaryOutcomeTimeFrame": "At base line and at week 12,24,36 and 48"
          },
          {
            "SecondaryOutcomeMeasure": "MELD score",
            "SecondaryOutcomeTimeFrame": "At base line and at week 4,8,12,24,36 and 48"
          },
          {
            "SecondaryOutcomeMeasure": "Number of participants with improvement of clinical symptoms",
            "SecondaryOutcomeDescription": "clinical symptoms including fatigue (Fatigue Impact Score, FIS) and pruritus ( Visual Analog Scale ,VAS)",
            "SecondaryOutcomeTimeFrame": "At base line and at week 4,8,12,24,36 and 48"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nWritten informed consent\nPrimary Biliary Cirrhosis (according to the criteria defined by AASLD practice guidelines , Hepatology, 2009;50:291-308 )\nNegative pregnancy test (female patients in fertile age)\n\nExclusion Criteria:\n\nHepatocellular carcinoma or other Malignancies\nPregnant or lactating women\nViral Hepatitis ( HAB, HBV, HCV, et al )\nVital organs failure (Cardiac, Renal or Respiratory, et al)\nSepsis\nActive thrombosis in the portal or hepatic veins",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Fu-Sheng Wang, professor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "86-10-63879735",
            "CentralContactPhoneExt": "2015.12",
            "CentralContactEMail": "fswang302@163.com"
          },
          {
            "CentralContactName": "Zheng Zhang, Doctor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "86-10-63879735",
            "CentralContactPhoneExt": "2015.12",
            "CentralContactEMail": "Zhangzheng1975@yahoo.com.cn"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Fu-Sheng Wang, professor",
            "OverallOfficialAffiliation": "Beijing 302 Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Beijing 302 Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Beijing",
            "LocationState": "Beijing",
            "LocationZip": "100039",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Fu-Sheng Wang, professor",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "86-10-63879735",
                  "LocationContactPhoneExt": "2015.12",
                  "LocationContactEMail": "fswang302@163.com"
                },
                {
                  "LocationContactName": "Lifeng Wang, Doctor",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "86-10-63879735",
                  "LocationContactPhoneExt": "2015.12",
                  "LocationContactEMail": "wanglf76@gmail.com"
                },
                {
                  "LocationContactName": "Fu-Sheng Wang, Professor",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "9287980",
            "ReferenceType": "background",
            "ReferenceCitation": "Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997 Sep;113(3):884-90."
          },
          {
            "ReferencePMID": "19208346",
            "ReferenceType": "background",
            "ReferenceCitation": "Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, Houben MH, Witteman BJ, van Erpecum KJ, van Buuren HR; Dutch PBC Study Group. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009 Apr;136(4):1281-7. doi: 10.1053/j.gastro.2009.01.003. Epub 2009 Jan 14."
          },
          {
            "ReferencePMID": "20347176",
            "ReferenceType": "background",
            "ReferenceCitation": "Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol. 2010 May;52(5):745-58. doi: 10.1016/j.jhep.2009.11.027. Epub 2010 Feb 18. Review."
          },
          {
            "ReferencePMID": "20578151",
            "ReferenceType": "background",
            "ReferenceCitation": "Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology. 2010 Jul;52(1):349-59. doi: 10.1002/hep.23637."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000008103",
            "ConditionMeshTerm": "Liver Cirrhosis"
          },
          {
            "ConditionMeshId": "D000008105",
            "ConditionMeshTerm": "Liver Cirrhosis, Biliary"
          },
          {
            "ConditionMeshId": "D000005355",
            "ConditionMeshTerm": "Fibrosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000008107",
            "ConditionAncestorTerm": "Liver Diseases"
          },
          {
            "ConditionAncestorId": "D000004066",
            "ConditionAncestorTerm": "Digestive System Diseases"
          },
          {
            "ConditionAncestorId": "D000002780",
            "ConditionAncestorTerm": "Cholestasis, Intrahepatic"
          },
          {
            "ConditionAncestorId": "D000002779",
            "ConditionAncestorTerm": "Cholestasis"
          },
          {
            "ConditionAncestorId": "D000001649",
            "ConditionAncestorTerm": "Bile Duct Diseases"
          },
          {
            "ConditionAncestorId": "D000001660",
            "ConditionAncestorTerm": "Biliary Tract Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10255",
            "ConditionBrowseLeafName": "Liver Cirrhosis",
            "ConditionBrowseLeafAsFound": "Cirrhosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10257",
            "ConditionBrowseLeafName": "Liver Cirrhosis, Biliary",
            "ConditionBrowseLeafAsFound": "Primary Biliary Cirrhosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M7637",
            "ConditionBrowseLeafName": "Fibrosis",
            "ConditionBrowseLeafAsFound": "Cirrhosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10259",
            "ConditionBrowseLeafName": "Liver Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8035",
            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6407",
            "ConditionBrowseLeafName": "Digestive System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5171",
            "ConditionBrowseLeafName": "Cholestasis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5172",
            "ConditionBrowseLeafName": "Cholestasis, Intrahepatic",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4087",
            "ConditionBrowseLeafName": "Bile Duct Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4098",
            "ConditionBrowseLeafName": "Biliary Tract Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4683",
            "ConditionBrowseLeafName": "Primary Biliary Cholangitis",
            "ConditionBrowseLeafAsFound": "Primary Biliary Cirrhosis",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC06",
            "ConditionBrowseBranchName": "Digestive System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M4101",
            "InterventionBrowseLeafName": "Bilirubin",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}